Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Auteurs principaux: Qiao Liu (Auteur), Zhen Zhou (Auteur), Xia Luo (Auteur), Lidan Yi (Auteur), Liubao Peng (Auteur), Xiaomin Wan (Auteur), Chongqing Tan (Auteur), Xiaohui Zeng (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...